Agios Pharmaceuticals (FRA:8AP) Cyclically Adjusted FCF per Share: €-4.90 (As of Mar. 2026)


FRA:8AP Agios Pharmaceuticals Inc FRA:8AP
49 GF Score
Price €38.00
GF Value €74.76
! 5 Warning Signs
View Full Analysis

What is Agios Pharmaceuticals Cyclically Adjusted FCF per Share?

Agios Pharmaceuticals FRA:8AP +18.01% 49 Cyclically Adjusted FCF per Share is €-4.90 as of Mar. 2026. GuruFocus rates FRA:8AP with a GF Score™ of 49/100 and a GF Value™ of €74.76. The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Agios Pharmaceuticals's adjusted free cash flow per share for the three months ended in Mar. 2026 was €-1.761. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-4.90 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -9.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Agios Pharmaceuticals was -9.70% per year. The lowest was -11.50% per year. And the median was -10.60% per year.

As of today (2026-07-09), Agios Pharmaceuticals's current stock price is €38.00. Agios Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €-4.90. Agios Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is .


Agios Pharmaceuticals  (FRA:8AP) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Agios Pharmaceuticals Cyclically Adjusted FCF per Share Related Terms


Agios Pharmaceuticals Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Agios Pharmaceuticals's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Agios Pharmaceuticals Cyclically Adjusted FCF per Share Chart

Agios Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.71 -4.23 -4.69 -5.49 -5.22

Agios Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.53 -5.28 -5.09 -5.22 -4.90

FRA:8AP vs ABCL, KOD, IMNM: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Agios Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Agios Pharmaceuticals Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Agios Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Agios Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.


FRA:8AP
49GF Score
Agios Pharmaceuticals Inc FRA:8AP
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Agios Pharmaceuticals Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Agios Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-1.761/330.2130*330.2130
=-1.761

Current CPI (Mar. 2026) = 330.2130.

Agios Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 3.637 241.018 4.983
201609 -1.212 241.428 -1.658
201612 -1.180 241.432 -1.614
201703 -1.645 243.801 -2.228
201706 -1.143 244.955 -1.541
201709 -1.380 246.819 -1.846
201712 -1.311 246.524 -1.756
201803 -1.462 249.554 -1.935
201806 -1.020 251.989 -1.337
201809 -0.989 252.439 -1.294
201812 -1.136 251.233 -1.493
201903 -1.594 254.202 -2.071
201906 -1.348 256.143 -1.738
201909 -1.353 256.759 -1.740
201912 -1.411 256.974 -1.813
202003 -1.445 258.115 -1.849
202006 -0.926 257.797 -1.186
202009 -0.901 260.280 -1.143
202012 -0.593 260.474 -0.752
202103 -1.471 264.877 -1.834
202106 -1.598 271.696 -1.942
202109 -1.269 274.310 -1.528
202112 -1.444 278.802 -1.710
202203 -1.673 287.504 -1.922
202206 -1.315 296.311 -1.465
202209 -1.315 296.808 -1.463
202212 -1.138 296.797 -1.266
202303 -1.615 301.836 -1.767
202306 -1.108 305.109 -1.199
202309 -1.335 307.789 -1.432
202312 -1.192 306.746 -1.283
202403 -1.632 312.332 -1.725
202406 -1.190 314.175 -1.251
202409 -1.305 315.301 -1.367
202412 -2.178 315.605 -2.279
202503 -1.807 319.799 -1.866
202506 -1.317 322.561 -1.348
202509 -1.315 324.800 -1.337
202512 -1.425 324.054 -1.452
202603 -1.761 330.213 -1.761

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-4.90 mean?
Agios Pharmaceuticals (FRA:8AP) has a Cyclically Adjusted FCF per Share of €-4.90 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Agios Pharmaceuticals and its competitors.
Is Agios Pharmaceuticals' Cyclically Adjusted FCF per Share too high?
Agios Pharmaceuticals' current Cyclically Adjusted FCF per Share is €-4.90. Overall, Agios Pharmaceuticals has a GF Score™ of 49/100, reflecting its overall financial health beyond just this single metric.
How does Agios Pharmaceuticals' Cyclically Adjusted FCF per Share compare to ABCL and KOD?
Agios Pharmaceuticals' Cyclically Adjusted FCF per Share of €-4.90 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Agios Pharmaceuticals and its competitors. Agios Pharmaceuticals's current Cyclically Adjusted FCF per Share is €-4.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agios Pharmaceuticals stock overvalued right now?
Agios Pharmaceuticals (FRA:8AP) has a current Cyclically Adjusted FCF per Share of €-4.90. The stock's GF Value™ is €74.76, compared to a current price of €38.00 — trading 49.2% below its estimated fair value. The current Cyclically Adjusted FCF per Share is €-4.90. Agios Pharmaceuticals' overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Agios Pharmaceuticals (FRA:8AP), the current Cyclically Adjusted FCF per Share is €-4.90 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Agios Pharmaceuticals (FRA:8AP) Overvalued in 2026?

Based on GuruFocus' analysis, Agios Pharmaceuticals stock appears to be undervalued. The current stock price of €38.00 is trading 49.2% below its estimated GF Value™ of €74.76.

Key valuation signals for FRA:8AP:

  • Cyclically Adjusted FCF per Share: €-4.90
  • GF Value™: €74.76 vs. price of €38.00 (49.2% below fair value)
  • GF Score™: 49/100 with 5 warning signs

No single metric tells the full story. See the FRA:8AP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Agios Pharmaceuticals Business Description

Other Exchanges AGIO:USA0HB0:UK8AP:Germany
Address 88 Sidney Street, Cambridge, MA, USA, 02139
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
49GF Score

Get the complete analysis for FRA:8AP

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€38.00
Price
€74.76
GF Value